Condition
Amyloid Cardiomyopathy, Transthyretin-Related
Total Trials
4
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 3 (2)
Trial Status
Completed2
Active Not Recruiting1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03812172CompletedPrimary
Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations
NCT04988386Phase 3Active Not RecruitingPrimary
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
NCT07116473Phase 3Not Yet Recruiting
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT03294707Phase 1CompletedPrimary
Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10
Showing all 4 trials